LGC Standards – Your Trusted Partner for Drug Development Solutions
Bringing a drug to market is an enormous challenge, with average costs exceeding $860 million, projects stretching beyond a decade, and failure rates above 90%. At LGC Standards, we understand the pressures you face - from the need for high-quality, reproducible data that meets stringent regulations, to the challenge of tight timelines.
With over 40 years of proven expertise in complex organic synthesis and reference standards, leading pharmaceutical companies trust us to provide both custom compounds and expert support that de-risk development pipelines and keep research moving forward.
Scaling Up to Support You
In 2024, we opened our state-of-the-art 200,000 sq. Ft. Toronto Research Chemicals (TRC) facility in Toronto, staffed by more than 100 PhD- and MSc-qualified scientists. This expansion has strengthened our capabilities - enabling us to drive product innovation and further invest in our longstanding expertise in custom solutions - while streamlining operations for faster delivery.
Alongside our catalogue of over 100,000 compounds - including API standards, metabolites, impurities, and endogenous compounds, available in native and SIL forms – we provide a broad and flexible range of tailored solutions to support your research and development goals.
Specialist Support for Drug Safety and Pharmacokinetics
Stable Isotope Labelling
Drawing from decades of experience in the development of stable labelled isotope materials, we design bespoke standards with carefully selected and strategically positioned labels - including D, 13C, 15N, 18O, and multi-labelled compounds - to ensure reliable analysis in biological matrices such as blood, plasma and urine.
Bulk Synthesis
We produce API standards, metabolites and impurities, in quantities ranging from milligrams to kilograms, qualified to your exact specifications for drug safety evaluations.
Custom Molecules
Lead Optimisation
We work closely with you to develop custom molecules with precise structural modifications, enhancing selectivity, stability, and solubility to support lead optimisation and drug development. Our expertise includes complex multi-step synthesis and rigorous quality control - ensuring that you receive the high-purity materials you need for your research and regulatory compliance.
Custom Compound Libraries
We offer the synthesis of diverse compound libraries, tailored to your research needs - enabling faster screening, lead identification, and structure-activity relationship (SAR) studies.
Custom Standards, Batch Production and Inventory Management
Bespoke Reference Standards
Our custom reference standards, including working standards, are tailored to your internal quality specifications. With flexible unit sizes, customisable Certificates of Analysis, and pharmacopeia traceability, we support your analytical needs with precision and reliability.
Custom Batch Production
We produce tailored batches of reference standards in small or large quantities, meeting your exact requirements, ensuring consistency, and compliance with your quality requirements.
Worldwide Inventory Management
Combining bespoke production capabilities with our global supply chain solutions, our inventory management services ensure that you have the tools you need, when you need them.
Partner with LGC Standards
We are committed to supporting your success - delivering expert guidance, tailored solutions, and high-quality products to help you navigate your drug discovery and pharmaceutical manufacturing challenges with confidence.
Speak with our experts today and discover how we can support your work.
LGC. Science for a Safer World
About Drug Discovery Innovation Programme 2025
The Drug Discovery Innovation Programme is an exclusive, invitation-only event designed to connect leading scientists, researchers, and industry pioneers in a dynamic and collaborative environment.
Join us in person to gain insights from top experts in drug discovery and development, exploring the latest breakthroughs, emerging technologies, and innovative approaches shaping the future of the industry. With a forward-thinking agenda covering small molecule discovery, biologics, AI-driven translational medicine, and regulatory insights, DDIP 2025 will feature tailored sessions led by global leaders.
Bringing together visionaries from Johnson & Johnson Innovative Medicine, Regeneron Pharmaceuticals, Amgen, Novo Nordisk, AbbVie, GSK, Exelixis, Insilico Medicine, and many more, this event is your opportunity to expand your knowledge, network with key stakeholders, and accelerate your drug development journey.